Table 3.
Characteristics of Project DETECT part 2–group 2 and group 3 participants (September 2015 to March 2019) compared with current King County residents living with diagnosed HIV infection as of December 31, 2017.
| Characteristics | Project DETECTa group 2 and 3 participants n=294 n (%) | Current King County residents living with diagnosed HIV infection, Dec 2017b n=6907 n (%) | ||||
| Project DETECT part 2 participants |
|
|
||||
|
|
Group 2: patients with established HIV infection | 198 (67.3) | — | |||
|
|
Group 3: patients with acute or newly diagnosed HIV infection | 96 (32.7) | — | |||
| Referral site/process |
|
|
||||
|
|
AIDS Clinical Trial Unit/Madison Clinic | 241 (82.0) | — | |||
|
|
PHSKCc STDd clinic | 38 (12.9) | — | |||
|
|
Other site | 1 (0.3) | — | |||
|
|
Missing | 14 (4.8) | — | |||
| Age group in years |
|
|
||||
|
|
18-24 | 26 (8.8) | 122e (1.8) | |||
|
|
25-34 | 52 (17.7) | 948 (13.7) | |||
|
|
35-44 | 47 (16.0) | 1445 (20.9) | |||
|
|
45-54 | 74 (25.2) | 2209 (32.0) | |||
|
|
≥55 | 59 (20.1) | 2169 (31.4) | |||
|
|
Missingf | 36 (12.2) | 0 (0) | |||
| Race/ethnicity |
|
|
||||
|
|
Asian | 4 (1.4) | 303 (4.4) | |||
|
|
Black/African American | 84 (28.6) | 1340 (19.4) | |||
|
|
Hispanic/Latinxg | 39 (13.3) | 924 (13.4) | |||
|
|
Multiracial | 15 (5.1) | 387 (5.6) | |||
|
|
Native American | 10 (3.4) | 50 (0.7) | |||
|
|
Pacific Islander | 2 (0.7) | 27 (0.4) | |||
|
|
White | 94 (32.0) | 3876 (56.1) | |||
|
|
Missing | 46 (15.6) | 0 (0) | |||
| Current gender identity |
|
|
||||
|
|
Cisgender man | 232 (78.9) | 6004h (86.9) | |||
|
|
Cisgender woman | 43 (14.6) | 839h (12.1) | |||
|
|
Transgender woman | 4 (1.4) | 59 (0.9) | |||
|
|
Transgender man | 0 (0) | 5 (0.1) | |||
|
|
Nonbinary/genderqueeri | 4 (1.4) | — | |||
|
|
Missing | 11 (3.7) | 0 (0) | |||
| Gender of sex partners in last year |
|
|
||||
|
|
Cisgender male participants |
|
|
|||
|
|
|
Men only | 139 (47.3) | — | ||
|
|
|
Women only | 37 (12.6) | — | ||
|
|
|
Men and women | 18 (6.1) | — | ||
|
|
|
Men and other partners | 2 (0.7) | — | ||
|
|
|
Men and transgender men | 2 (0.7) | — | ||
|
|
|
Men, women, and transgender women | 2 (0.7) | — | ||
|
|
|
Men, women, and transgender men | 1 (0.3) | — | ||
|
|
|
Women and transgender men | 1 (0.3) | — | ||
|
|
|
Women and transgender women | 1 (0.3) | — | ||
|
|
|
Men, women, transgender men, and transgender women | 1 (0.3) | — | ||
|
|
Cisgender female participants |
|
|
|||
|
|
|
Men only | 29 (9.9) | — | ||
|
|
|
Women only | 1 (0.3) | — | ||
|
|
|
Men and women | 1 (0.3) | — | ||
|
|
|
Men and other partners | 2 (0.7) | — | ||
|
|
Transgender female participants |
|
|
|||
|
|
|
Men only | 3 (1.0) | — | ||
|
|
|
Men and nonbinary/genderqueer partners | 1 (0.3) | — | ||
|
|
Nonbinary/genderqueer participants |
|
|
|||
|
|
|
Men only | 1 (0.3) | — | ||
|
|
|
Men and women | 1 (0.3) | — | ||
|
|
|
Men and nonbinary/genderqueer partners | 1 (0.3) | — | ||
|
|
|
Men, women, transgender men, and other partners | 1 (0.3) | — | ||
|
|
|
No sex partners | 36 (12.2) | — | ||
|
|
|
Missing | 13 (4.4) | — | ||
| Sexual orientation |
|
|
||||
|
|
Bisexual | 34 (11.6) | — | |||
|
|
Gay | 128 (43.5) | — | |||
|
|
Queer | 4 (1.4) | — | |||
|
|
Straight/heterosexual | 91 (31.0) | — | |||
|
|
Other | 1 (0.3) | — | |||
|
|
Missing | 36 (12.2) | — | |||
| Self-reported ART j status |
|
|
||||
|
|
ART-naïve | 104 (35.4) | — | |||
|
|
ART-experienced but not currently on ART | 11 (3.7) | — | |||
|
|
Currently on ART | 168 (57.1) | — | |||
|
|
Missing | 11 (3.7) | — | |||
| HIV RNA level at study visit |
|
|
||||
|
|
Undetectable or <40 copies/mL | 144 (49.0) | — | |||
|
|
40-200 copies/mL | 14 (4.8) | — | |||
|
|
201-1000 copies/mL | 10 (3.4) | — | |||
|
|
>1000 copies/mL | 119 (40.5) | — | |||
|
|
Specimen not availablek | 7 (2.4) | — | |||
| Self-reported STD diagnosis in previous 3 months |
|
|
||||
|
|
Chlamydia | 18 (6.1) | — | |||
|
|
Gonorrhea | 23 (7.8) | — | |||
|
|
Syphilis | 22 (7.5) | — | |||
|
|
Other STD | 8 (2.7) | — | |||
|
|
Missing | 15 (5.1) | — | |||
| Substance use in previous 3 months |
|
|
||||
|
|
Injection |
|
|
|||
|
|
|
Heroin | 38 (12.9) | — | ||
|
|
|
Methamphetamine | 69 (23.5) | — | ||
|
|
|
Other drugs | 6 (2.0) | — | ||
|
|
Noninjection |
|
|
|||
|
|
|
Methamphetamine | 80 (27.2) | — | ||
|
|
Missing | 15 (5.1) | — | |||
aDETECT: Diagnostic Evaluation To Expand Critical Testing Technologies.
bData are from the HIV/AIDS Epidemiology Unit, Public Health–Seattle & King County and the Infectious Disease Assessment Unit, Washington State Department of Health. HIV/AIDS Epidemiology Report 2018, Volume 87.
cPHSKC: Public Health–Seattle & King County.
dSTD: sexually transmitted disease.
eIncludes unspecified number of persons ages 13 to 17 years.
fAge of participants is confirmed by medical record in the absence of a part 2 behavioral survey.
gPersons who identified as Hispanic or Latinx ethnicity were classified as Hispanic/Latinx regardless of race.
hData do not specify cisgender.
iCategory not used in PHSKC HIV/AIDS Epidemiology Report 2018.
jART: antiretroviral therapy.
kNo venipuncture whole blood was drawn at the study visit.